Could a new pill quiet chronic pain? early trial puts it to the test
NCT ID NCT06155487
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This Phase 1 trial evaluates the safety, tolerability, and how the body processes an experimental oral drug called AJH-2947. It involves healthy Korean or Caucasian men aged 19 to 55, who receive either the drug or a placebo. The study aims to determine safe dosing and preliminary effects on pain perception, potentially informing future treatments for chronic pain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AJH-2947 tablets
- What this could lead to
- If successful, this early trial could pave the way for a new oral medication to manage chronic pain.
- What could go wrong
- This is a small, early-phase study focused on safety and dosing, not effectiveness. The drug may not prove safe or effective in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PAIN SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults
- Could a new drug alter the fate of common medications?